Concord Biotech Ltd's Q4FY25 Quarterly Results

Result Summary

• Concord Biotech Ltd reported a 27.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.8%.
• Its expenses for the quarter were up by 24.6% QoQ and 25.0% YoY.
• The net profit increased 25.2% QoQ and increased 3.9% YoY.
• The earnings per share (EPS) of Concord Biotech Ltd stood at 9.1 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Concord Biotech Ltd is a company operating in the biotechnology sector, focusing on the development and commercialization of bio-pharmaceutical products. This industry is characterized by high levels of research and development activity, aiming to innovate and bring new therapeutic solutions to the market. It is common for companies in this industry to engage in the production of active pharmaceutical ingredients (APIs), biosimilars, and other related products. However, specific details about Concord Biotech Ltd's main products or any recent major developments are not available in the provided data.

Revenue

In the fourth quarter of the fiscal year 2025 (Q4FY25), Concord Biotech Ltd reported a total income of ₹329.78 crores. This represents a significant increase of 27.4% compared to the previous quarter (Q3FY25), where the total income was ₹258.95 crores. Year-over-year, the total income increased by 15.8% from ₹284.79 crores in Q4FY24. These figures indicate a robust revenue growth for the company over both the quarter and the year.

Profitability

For Q4FY25, Concord Biotech Ltd achieved a profit before tax (PBT) of ₹130.92 crores, up 31.8% from the previous quarter's ₹99.32 crores and a 4.2% increase from ₹125.62 crores in Q4FY24. The company incurred a tax expense of ₹33.70 crores, which is a 33.6% increase quarter-over-quarter and a 4.9% increase year-over-year. Consequently, the profit after tax (PAT) for Q4FY25 stood at ₹95.02 crores, reflecting a 25.2% increase from the previous quarter and a 3.9% rise from the same quarter last year. Earnings per share for the quarter were ₹9.10, marking a 24.7% increase QoQ and a 3.4% increase YoY.

Operating Metrics

The total expenses for Concord Biotech Ltd in Q4FY25 were ₹198.86 crores, which increased by 24.6% from Q3FY25's ₹159.63 crores and by 25.0% from ₹159.15 crores in the same quarter last year. This rise in expenses may reflect increased operational activities or cost factors. The data does not provide specific insights into the company's operating efficiency ratios or other detailed financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio. The provided financial metrics focus primarily on income, expenses, and profitability measures.